LDS/Medical Tests/Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Genetic Mutation Analysis

Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Genetic Mutation Analysis

Short-chain acyl-CoA dehydrogenase (SCAD) is one of the enzymes involved in mitochondrial -oxidation of short-chain fatty acids (C6 and C4) and is encoded by the ACADS gene, located on chromosome 12q22. Mutations in ACADS results in decreased SCAD activity which may cellular energy generation, particularly during fasting state. Previously, SCAD deficiency was associated with a wide variety of symptoms appearing in infancy or childhood including vomiting, hypoglycemia, lethargy, poor feeding, and failure to thrive, hypotonia, seizures, developmental delay, and microcephaly. Subsequently, however, it has been determined that up to 14% of the population are homozygous or compound heterozygous for two common polymorphisms, c.511C>T and/or c.625G>A that reduce enzyme activity and lead to biochemical findings of SCAD without clinical symptoms. Another common mutation is c.319C>T, reported to be a common cause of SCAD deficiency in the Ashkenazi population, but was also found in individuals of other ethnic groups. As all infants detected on Newborn Screening (NBS) have remained asymptomatic, many now consider SCAD to be a benign biochemical phenotype rather than a pathologic disorder.

Since deficiency of SCAD inhibits the oxidation of butyryl-CoA, it gets diverted to alternative pathway to form ethylmalonic acid (EMA) and conjugated with carnitine and glycine. Therefore, the most useful biochemical marker of SCAD deficiency are EMA and butyrylglycine in urine and C4-acylcarnitine (butyrylcarnitine) in plasma which is used in newborn screening. SCAD deficiency needs to be differentiated from ethylmalonic encephalopathy, a rare fatal mitochondrial disorder. Urine organic acids, urine acylglycine and plasma acylcarnitine profiles can be used to differentiate among these conditions. Molecular genetic analysis of the ACADS gene can be used in doubtful conditions to confirm the biochemical phenotype of SCAD deficiency.

  • To confirm the diagnosis of Short-chain acyl-CoA dehydrogenase (SCAD) deficiency
  • Useful in screening individuals with family history of SCAD deficiency
  • acyl-CoA dehydrogenase deficiency in newborn screening
  • Useful in differential diagnosis to rule out ethylmalonic encephalopathy
Positive for mutation is consistent with SCAD deficiency.

No pathogenic variants or mutation detected (Negative for mutation analyzed)

Polymerase Chain Reaction (PCR)/DNA Sequence Analysis, allele specific primer extension (ARMS).

Whole blood (EDTA, Heparin), Amniotic fluid.

Stability

  • Ambient: 48 hours
  • Refrigerated: 7 days
  • Frozen: unacceptable
Urine and plasma C4 acylcarnitine (butyrylcarnitine), Urine organic acids, Urine acylglycine, and Plasma acylcarnitine profiles.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login